Algernon Pharmaceuticals Inc. (CSE:AGN)

Canada flag Canada · Delayed Price · Currency is CAD
0.0800
+0.0050 (6.67%)
Oct 9, 2025, 2:47 PM EDT
6.67%
Market Cap2.57M
Revenue (ttm)n/a
Net Income (ttm)-1.76M
Shares Out34.26M
EPS (ttm)-0.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,000
Average Volume31,103
Open0.0750
Previous Close0.0750
Day's Range0.0750 - 0.0800
52-Week Range0.0550 - 0.1225
Beta1.65
RSI57.52
Earnings DateNov 26, 2025

About Algernon Pharmaceuticals

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. It pipeline includes Ifenprodil, which is in Phase 2b clinical trial for the treatment of idiopathic pulmonary fibrosis and chronic cough; repirinast, which is in Phase 1 clinical trial for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine, which is i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol AGN
Full Company Profile

Financial Performance

Financial Statements

News

Catalyst MedTech Launches "Connect" Program to Expand Access to Advanced Imaging; Announces Initial Partnership with Algernon Pharmaceuticals

PITTSBURGH , Oct. 7, 2025 /PRNewswire/ -- Catalyst MedTech today announced the launch of its new Connect program, an initiative that brings together collaborators seeking to advance patient care with ...

2 days ago - PRNewsWire

Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer's Detection

VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...

14 days ago - GlobeNewsWire

Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer's Detection

VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...

14 days ago - Benzinga

Algernon Announces Preferred Share Class Approved at Annual and Special Meeting

VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...

20 days ago - GlobeNewsWire

Algernon Pharmaceuticals Announces Name Change to Algernon Health

VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company a...

5 weeks ago - GlobeNewsWire

Algernon Announces Closing of the Private Placement Financing

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

2 months ago - GlobeNewsWire

Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

3 months ago - GlobeNewsWire

Algernon Announces $1M Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “...

4 months ago - GlobeNewsWire

Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinica...

5 months ago - GlobeNewsWire

Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology

VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinica...

5 months ago - GlobeNewsWire

Algernon Announces Warrant Extension

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

5 months ago - GlobeNewsWire

Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease

VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharm...

6 months ago - GlobeNewsWire

Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing

VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pha...

7 months ago - GlobeNewsWire

Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study

VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage phar...

8 months ago - GlobeNewsWire

Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare's USD $170K Equity Investment

VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage phar...

8 months ago - GlobeNewsWire

Algernon CEO Discusses Ifenprodil Sale to Seyltx and DMT as a Treatment for Stroke and TBI

Christopher Moreau, CEO of Algernon Pharmaceuticals, discusses the company’s sale of Ifenprodil to Seyltx, and their current focus on DMT as a treatment for stroke and traumatic brain injury.

10 months ago - BNN Bloomberg

How Algernon Pharmaceuticals is Unlocking Sub-Psychedelic DMT for Stroke and TBI Treatment

In response to this global need for more universal and broadly deliverable, frontline treatments, Algernon Pharmaceuticals Inc. (CSE: AGN | OTCQB: AGNPF | FSE: AGW0) (AGN Pharma), through its wholly-o...

10 months ago - BNN Bloomberg

Algernon Announces Warrant Extension

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR  DISSEMINATION IN THE UNITED STATES

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals Announces Closing of Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKF...

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals Announces Increase to Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKF...

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals Announces Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKF...

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services

VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharm...

1 year ago - GlobeNewsWire

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pha...

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite investors ...

1 year ago - GlobeNewsWire

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharm...

1 year ago - GlobeNewsWire